Podcasts about Lille

  It's been said that taking the Eurostar (which runs under the English Channel, connecting London to Brussels, Paris, Lille, Rotterdam and Amsterdam) is much more like taking a plane ride than taking a train ride, and in many respects, I would have to agree. Why? It's swift, it's non-stop and there is wonderful service and amenities for comfort as you drift along in either direction. Today's episode/post is for the first-time traveler choosing to take the Eurostar and especially for those of you like me, who don't live in Europe or Britain and want to see as much of the two countries that you love during one trip with ease. I booked my first ticket on the Eurostar in 2012, boarding in London, destined for Paris. Riding Standard (aka Coach) with my traveling companion, the ease of having your luggage with you, sitting in comfortable seats with spacious seating arrangements all the while knowing the only stop will be your stop eased my mind as it was the first time I had traveled abroad to Europe since 2000. Fast forward to 2022, and I booked our Standard Premiere tickets (there are three classes - Standard, Standard Premiere and Business Premiere), leaving Paris, departing for London. The upgrade was lovely and worth the additional space, a bit quieter (although Standard was fairly quiet as well), and the upgrade in dining service was oh, so good. But I am getting ahead of myself. ~The Simple Sophisticate, episode #338 ~Subscribe to The Simple Sophisticate:  iTunes | Stitcher | iHeartRadio | YouTube | Spotify | Amazon Music    

Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

Du lundi au vendredi, de 18h à 20h, « Rothen s'enflamme » est LE nouveau rendez-vous du foot ! Avec sa liberté de ton et sa passion, Jérôme Rothen lancera des débats enflammés avec sa Dream Team d'anciens joueurs. Il accueillera également les plus grandes stars du foot dans une ambiance de vestiaire entre chambrage et discussions passionnées. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

Est-ce vraiment pertinent de planter des oliviers à Lille ? Que signifie être au service de la nature lorsque l'on conçoit un jardin ? Dans la continuité de la pensée de Gilles Clément, Nicolas Deshais-Fernandez, fondateur de l'Atelier NDF, s'inscrit dans cette nouvelle génération de paysagiste qui croit au jardin naturaliste et qui met en lumière une nouvelle palette végétale, spontanée, sauvage, libre, frugale, fertile et locale. Penser un jardin cela doit être tout autre chose que concevoir une palette végétale horticole grandement standardisée aujourd'hui. Retrouver l'histoire d'un territoire dans un jardin, comme meilleur moyen de découvrir la beauté de la nature. Une discussion à bâtons rompus pour comprendre tout ce qui se trâme dès qu'il est question du sort d'un arbre dans un projet d'architecture !

Feargal Brennan is joined by Marley Anderson and Joel Tudor for Wednesday's podcast! Manchester United will not be pursuing a move for Marko Arnautovic this summer but could they make a swoop for Atletico Madrid striker Alvaro Morata to solve their attacking issues? Everton boss Frank Lampard has brought in Wolves skipper Conor Coady on loan at Goodison Park alongside Belgian star Amadou Onana from Lille. Plus the guys answer your social media Premier League questions! Learn more about your ad choices. Visit megaphone.fm/adchoices

Découvrez le travail de Chloé sur https://chloedeloison.myportfolio.com/ https://www.instagram.com/kurho_art/ https://www.artstation.com/kurho-art Le podcast au format vidéo est disponible sur http://youtube.com/benjamincerbaiet https://odysee.com/@benjamincerbai:f Callipeg, notre application d'animation 2D pour iPad, est disponible ici : https://apps.apple.com/app/callipeg/id1456172656

L'After foot, c'est LE show d'après-match et surtout la référence des fans de football depuis 15 ans ! Les rencontres se prolongent tous les soirs avec Gilbert Brisbois et Nicolas Jamain avec les réactions des joueurs et entraîneurs, les conférences de presse d'après-match et les débats animés entre supporters, experts de l'After et auditeurs. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h-9h), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

08.08.2022 // ManU verliert durch Groß-Doppelpack | Werner vor RB-Rückkehr | Nächster Portugiese für die Wolves | Onana vor Wechsel von Lille zu Everton | Paris investiert in die Jugend | Spieler der Woche | ... und viele weitere Einblicke aus der heißen Transferphase! In diesem Podcastformat diskutieren wir innerhalb von fünfzehn Minuten die interessantesten Partien vom Wochenende, analysieren Top-Leistungen spannender Akteure und bringen dir Entwicklungen relevanter Teams näher - vor allem basierend auf den Topligen aus England, Spanien, Italien und Frankreich. Den Abschluss bildet das Team sowie der Spieler der Woche. Du möchtest selbst die Spiele vom Wochenende anhand von Daten analysieren? Wir zeigen Dir, wie es funktioniert! In unserem Online-Kurs gibt es über 4 Stunden aufschlussreiches Lehrmaterial, welches im Anschluss praktisch angewendet werden kann. Klickt rein unter: https://www.createfootball.com/online-kurs/

08.08.2022 // ManU verliert durch Groß-Doppelpack | Werner vor RB-Rückkehr | Nächster Portugiese für die Wolves | Onana vor Wechsel von Lille zu Everton | Paris investiert in die Jugend | Spieler der Woche | ... und viele weitere Einblicke aus der heißen Transferphase! In diesem Podcastformat diskutieren wir innerhalb von fünfzehn Minuten die interessantesten Partien vom Wochenende, analysieren Top-Leistungen spannender Akteure und bringen dir Entwicklungen relevanter Teams näher - vor allem basierend auf den Topligen aus England, Spanien, Italien und Frankreich. Den Abschluss bildet das Team sowie der Spieler der Woche. Du möchtest selbst die Spiele vom Wochenende anhand von Daten analysieren? Wir zeigen Dir, wie es funktioniert! In unserem Online-Kurs gibt es über 4 Stunden aufschlussreiches Lehrmaterial, welches im Anschluss praktisch angewendet werden kann. Klickt rein unter: https://www.createfootball.com/online-kurs/ Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen? Dann schaue auf www.kostenlos-hosten.de und informiere dich. Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten.

08.08.2022 // ManU verliert durch Groß-Doppelpack | Werner vor RB-Rückkehr | Nächster Portugiese für die Wolves | Onana vor Wechsel von Lille zu Everton | Paris investiert in die Jugend | Spieler der Woche | ... und viele weitere Einblicke aus der heißen Transferphase! In diesem Podcastformat diskutieren wir innerhalb von fünfzehn Minuten die interessantesten Partien vom Wochenende, analysieren Top-Leistungen spannender Akteure und bringen dir Entwicklungen relevanter Teams näher - vor allem basierend auf den Topligen aus England, Spanien, Italien und Frankreich. Den Abschluss bildet das Team sowie der Spieler der Woche. Du möchtest selbst die Spiele vom Wochenende anhand von Daten analysieren? Wir zeigen Dir, wie es funktioniert! In unserem Online-Kurs gibt es über 4 Stunden aufschlussreiches Lehrmaterial, welches im Anschluss praktisch angewendet werden kann. Klickt rein unter: https://www.createfootball.com/online-kurs/ Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen? Dann schaue auf www.kostenlos-hosten.de und informiere dich. Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten.

Opening weekend of a brand new English Premier League season left Brendan Dunlop, Craig Forrest, Jimmy Brennan and James Sharman with so much to talk about, we literally delivered the longest weekend recap episode in show history. Cristiano Ronaldo had all the headlines before Manchester United's 2-1 loss to Brighton & Hove Albion, but CR7 couldn't steal the headlines once he came off the bench. Erik ten Hag's start at Old Trafford began with a punch to the gut, courtesy of BHAFC's Pascal Gross, who is addicted to scoring against Man Utd. Erling Haaland got off to a flying start as Man City ruined Craig Forrest's Sunday. Naturally our favourite goalkeeper had a lot to say about how David Moyes will have to manage goalkeepers Łukasz Fabiański and Alphonse Areola this season. Jimmy finds new ways to be clever with words, despite Nottingham Forest's disappointing start to life back in the Premier League.    Despite Darwin Núñez's dazzling start to life at Liverpool, Sharms is miserable and reveals a deep disdain for use of the traditional German character eszett, and the Spanish eñe. Dunny is deflated by Aston Villa's season opening loss to Bournemouth, though the rest of the crew back Steven Gerrard to get it right. Wonger is hilariously optimistic about Brentford's chances this season. The boys think that Bayern Munich have already won the Bundesliga after throttling Europa League winners Eintracht Frankfurt, on the same weekend Jonathan David lit up Ligue 1 with Lille and Lionel Messi scored a marvelous bicycle kick goal. And Lorenzo Insigne opened his MLS goal scoring account in dramatic fashion, as Toronto FC did something they hadn't done in over a year - win on the road.      Presenters: James Sharman, Craig Forrest, Jimmy Brennan, and Brendan Dunlop with Dan Wong Voice Over Talent: Jeff Cole This podcast has content that may use words and share tales that offend, please feel free to use your best discretion.  Parental discretion is advised.   Be advised this episode includes explicit language.

Skuespiller, forfatter og dramatiker Johannes Lilleøre havde i første omgang flere at vælge imellem, da vi spurgte ham, hvem der er hans kunstneristiske idol. Og så alligevel ikke, for filminstruktør David Lynch er en evig inspiration for Lilleøre, når Lynch ustandselig stiller spørgsmålstegn ved, hvad der er godt og ondt. Hør Johannes Lilleøre fortælle om David Lynch. Vært: Tore Leifer.

When everything comes at once, everything drops at once! Moving from England across the Channel, we take to France to look at life in Ligue 1 this season - and we're joined by the expert analysis of Alex Collings, of the Football Per 90 Podcast and a writer for Scouted Football. We pose five questions ahead of the season beginning: Can PSG break their points record (on back of a lot of hype and smart summer) Who is the best of the rest? What can we expect from Paulo Fonseca & Lille?  Who is the biggest regression candidate? Who is your tip for breakout star? There's also talk on the links to Amadou Onana, some revisiting of last year's thoughts and a discussion of Takumi Minamino's new role at Monaco. It's Ranks! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Vi dukker inn i kvinnelige forfatteres fantasy og science fiction univers med besøk fra vår gjenganger Vilde, som har satt seg som mål å lese mer fantasy av kvinnelige forfattere i 2022. Rune deler gode erfaringer fra butikken og Audhild har lest seg litt opp på historien til forfatterskapene i sjangeren og prøvd seg på en klassiker! Den lille podkasten er en podkastserie fra Haugesund Folkebibliotek i samarbeid med Den Lille Bokbutikken. Fokus her er det fantastiske leserunivers i Fantasy, Science Fiction, Dystopier og Tegneserier for ungdom og voksne. Denne episoden ble tatt opp på Den Lille Bokbutikken i Haraldsgaten i Haugesund sentrum. Gjester er: Vilde K. Bakkvig, Rune Vika og Audhild Tjugen - Redigert av Audhild Tjugen Intro og outro sangen er fra sangen "Angst" fremført av Månen har dotte ner, skrevet av Helge Toft, produsert av Kjetil Ulland, publisert av Haugesund Records. Brukt med tillatelse fra Helge Toft. Bilde tegnet av Trine Sørbø. Medier nevnt i episoden: Robin Hobb - "Ship of Magic" Kameron Hurley - "The Mirror Empire" og "The Light Brigade" Kate Elliott - "The Crown of Stars"-serien: Første bok "King's dragon" George R.R. Martin - "A Game of Thrones" ( engelsk / norsk / grafisk ) Siri Pettersen - "Ravneringene"-serien: Første bok "Odinsbarn" Naomi Novic - "The Scholomance"-serien: Første bok "A deadly education" Ursula Le Guin - "Earthsea" / "Jordsjø-krøniken" Diana Wynne Jones - "Howl's moving castle" og "Dark Lord of Derkholm" Studio Ghibli - "Howl's Moving Castle" og "Tales from Earthsea" Mary Shelley - "Frankenstein" (norsk) Margaret Cavendish - "The Blazing World" eller "Descriptions of a New World" Sheridan Le Fanu - "Carmilla" Fritz Lang / Thea von Harbou - "Metropolis" R.F. Kuang - "The Poppy War" N. K. Jemisin - "The Hundred Thousand Kingdoms" Katherine Addison - "The Goblin Emperor" --- Send in a voice message: https://anchor.fm/haugesundbibliotek/message

TK har invitert Tommy Ballestad, lokalpolitiker fra Skien, på kanotur opp Lilleælva. Bonuspreik gir deg også motiverende øyeblikk, og et lite krydder til vår Motivasjonspreik --- Send in a voice message: https://anchor.fm/motivasjonspreik/message

Matt and Paddy converge to talk a wild few days. Paddy has the latest as Amadou Onana from Lille and Idrissa Gueye look set to join. The lads also look at Chelsea and who will lead the line. Learn more about your ad choices. Visit megaphone.fm/adchoices

On est mercredi, c'est le mercato : bienvenue dans Mercredi Mercato. Cette semaine, Glenn Ceillier et Julien Pereira vous éclairent sur les derniers sujets transferts. Premier sujet : comment juger le mercato du Paris Saint-Germain ? Le club de la capitale est sur le point de faire signer Renato Sanches en provenance de Lille. Un choix intéressant qui vient compléter le mercato cohérent du PSG selon nos journalistes avec les arrivées de Vitinha, Ekitike et Mukiele. Ensuite, nos journalistes se penchent sur le cas Alexis Sanchez. Le Chilien est sur le point de rejoindre l'Olympique de Marseille. Pour évoquer le cas de l'attaquant, Guillaume Maillard-Pacini vient nous livrer son analyse sur le joueur. Dans quel état physique est-il ? Que peut-on en attendre du côté de l'OM ? Des réponses claires à venir. Troisième et dernier sujet : le cas de Frenkie de Jong, poussé vers la sortie au FC Barcelone. Le Néerlandais se verrait bien rester mais le club a besoin de s'en séparer. Un comportement limite selon Glenn Ceillier. On vous explique tout ça. Mercredi Mercato est à retrouver tous les mercredis sur toutes les plateformes d'écoute et ici en extraits vidéo. Vous pouvez réagir à cet épisode sur notre page Twitter. Retrouvez tous les podcasts d'Eurosport ici. Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

Renato Sanches devrait être un joueur du PSG. Après trois saisons à Lille, le milieu de terrain portugais va retrouver son ancien entraîneur à Lille avec lequel il a été champion de France : Christophe Galtier. Renato Sanches débarque-t-il dans la peau d'un futur titulaire au PSG ? Avec Vitinha, Verratti, Paredes et potentiellement une nouvelle recrue au PSG, comme va s'articuler le milieu de terrain de Paris ? Dans le même temps, Wijnaldum devrait quitter la capitale pour rejoindre l'AS Roma.

#BREAKINGNEWS as Renato Sanches completes his transfer from LOSC Lille to Paris Saint-Germain for 15m Euros. Reactions & analysis to the deal now on our latest show. Check it out! Late Night Football is also available on the following channels: iTunes - https://podcasts.apple.com/ca/podcast/the-late-night-football-show/id1510270353 Spotify - https://open.spotify.com/show/0PPgcvuaWbUMYWR9WWzH43 If you're a sports fan and have a Facebook account, check out Fox in the Box, a great group for sports-minded discussions and opinions. Click here - https://www.facebook.com/groups/FoxInTheBoxFC You can also follow us on the following channels: Twitter - https://twitter.com/HumourFooty Facebook - https://www.facebook.com/Late-Night-Football-113739890317495

Les deux premiers épisodes étaient présentés en avant-première à Séries Mania 2022, la saison entière est disponible sur Salto, c'est Syndrome E dont on vous avait déjà parlé avec une première interview de Jennifer Decker qui interprète l'héroïne Lucie Hennebelle. La série adaptée du roman de Franck Thilliez est toujours disponible sur Salto et cette fois-ci c'est l'auteur lui-même qui nous parle du projet. Il en profite pour parler d'écriture en général et de ses goûts en matière de séries. https://dai.ly/k1IZfPNVJ5o6ZHyaVVA [bs_show url="le-syndrome-e"] La prochaine édition de Séries Mania se tiendra du 17 au 24 mars 2023, toujours à Lille et en ligne !

Les deux premiers épisodes étaient présentés en avant-première à Séries Mania 2022, la saison entière est disponible sur Salto, c'est Syndrome E dont on vous avait déjà parlé avec une première interview de Jennifer Decker qui interprète l'héroïne Lucie Hennebelle. La série adaptée du roman de Franck Thilliez est toujours disponible sur Salto et cette fois-ci c'est l'auteur lui-même qui nous parle du projet. Il en profite pour parler d'écriture en général et de ses goûts en matière de séries. https://dai.ly/k1IZfPNVJ5o6ZHyaVVA [bs_show url="le-syndrome-e"] La prochaine édition de Séries Mania se tiendra du 17 au 24 mars 2023, toujours à Lille et en ligne !

This week, please join authors Paul Ridker and Eric Van Belle, editorialist Robert Harrington, and Guest Editor Allan Jaffe as they discuss the original research articles "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy" and “Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort” and the editorial "Trials and Tribulations of Randomized Clinical Trials." Dr. Carolyn Lam:             Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the Journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center, and Duke National University of Singapore. Dr. Greg Hundley:           And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam:             It's double feature time Greg. We've got two totally unique and interesting papers that we'll be discussing. The first, a biomarker substudy from the REDUCE-IT trial, that is looking at the effects of randomized treatment with icosapent ethyl, versus a mineral oil comparator, on inflammatory biomarkers. Now, don't use roll your eyes at me, because I'm telling you, this has results that you may not expect, and very, very important clinical implications, and implications for clinical trials. The second paper, very much up your alley, Greg, is a prospective MRI study of cerebral microbleeds during TAVR. But okay, enough now to whet your appetite, let's now just first grab coffees, and discuss the other papers and the issue, shall we? Dr. Greg Hundley:           You bet, Carolyn. And how about if I go first? Dr. Carolyn Lam:             Please. Dr. Greg Hundley:           So, Carolyn, my first paper comes from a group of investigators led by Dr. Araz Rawshani from the Institute of Medicine, and it included 715,143 patients with diabetes, registered in the Swedish National Diabetes Register, and compared them with over two million match controls, randomly selected from the general population, to determine the role of diabetes in the development of valvular heart disease, and particularly, the relation with risk factor control. Dr. Carolyn Lam:             Huh? Interesting, diabetes and valve disease. All right. What did they find, Greg? Dr. Greg Hundley:           Right, Carolyn. So they found, that individuals with type one and two diabetes, have greater risk for stenotic lesions. Whereas, risk for valvular regurgitation was lower in type two diabetes. Patients with well controlled cardiovascular risk factors, continued to display higher risk for valvular stenosis, without a clear stepwise decrease in risk between various degrees of risk factor control. So Carolyn, diabetes and a link with valvular heart disease. Dr. Carolyn Lam:             Wow. Really interesting, Greg. Thanks. Well, the next paper is a preclinical study with really interesting clinical implications. Now, we know the human heart has limited capacity to regenerate new cardiomyocytes, and that this capacity declines with age. Now, because loss of cardiomyocytes may contribute to heart failure, it is important to explore how stimulating endogenous cardiac regeneration, to favorably shift the balance between loss of cardiomyocytes and birth of new cardiomyocytes, occurs in the aged heart. Now, these authors, Doctors Rosenzweig, from Massachusetts General Hospital, and Dr. Lee from Harvard University and colleagues, previously showed that cardiomyogenesis can be activated by, guess what? Exercise in the young adult mouse heart. However, whether exercise also induces cardiomyogenesis in aged hearts, however, is not yet known. So in today's paper, the authors aim to investigate the effect of exercise on generation of new cardiomyocytes in the aged heart. And here, we're talking about 20 month old mice, who were subjected to an eight week voluntary running protocol, and age matched sedentary animals who served as controls. Dr. Greg Hundley:           Wow, Carolyn. Really interesting evaluation of exercise on cardiomyogenesis. So what did they find? Dr. Carolyn Lam:             Endogenous cardiomyogenesis can be stimulated by exercise in aged hearts. Comparative global transcriptional analysis further revealed, that exercise and age specific changes occurred in gene programs. The regulator of calcineurin RCAN1.4 was specifically found to be induced with exercise in aged hearts, and was accompanied by reduced calcineurin activity. So what's a take-home message? Exercise induced cardiomyogenesis may counter the increased cardiomyocyte loss and reduced cardio myogenic capacity in elderly patients. Dr. Greg Hundley:           Great, Carolyn. Well from the mail bag, there's an exchange of letters to the editor from Professor Zhou and Veith regarding a prior letter to the editor from Professor Jin and associates, pertaining to the previously published article “SPARC, A Novel Regulator of Vascular Cell Function in Pulmonary Hypertension.” And also, there's a Perspective piece, from Professor Mentz entitled, “Catastrophic Disruptions in Clinical Trials.” Dr. Carolyn Lam:             There's also a Research Letter by Dr. Kumar on [entitled] “von Willebrand Factor Is Produced Exclusively by Endothelium, Not Neointima, in Occlusive Vascular Lesions in Both Pulmonary Hypertension and Atherosclerosis.” There's also this beautiful tour of Cardiology News from the literature, from Tracy Hampton, which ranges from a study linking COVID-19 to higher long term cardiovascular risks, which was published in Nature Med, to uncovering alternative metabolic pathways involving cell fate transitions, published in Nature, to designing an autonomous biohybrid fish, from human stem cell derived cardiac muscle cells, that was published in Science. Wow. Isn't that amazing, Greg? Well, let's get on now though, to our two feature papers. Shall we? Dr. Greg Hundley:           You bet. Welcome listeners, to these two feature discussions on this particular day. And our first feature today, we have with us Dr. Paul Ridker, from Brigham and Women's Hospital in Boston, Massachusetts. Dr. Bob Harrington, from Stanford University in California. And also, Dr. Allan Jaffe, from Rochester, Minnesota. Welcome to you all. And Paul, we're going to start for you. Can you describe for us, the background information that really went into the construct of your study, and what was the hypothesis that you wanted to address? Dr. Paul Ridker: Sure, Greg. So first of all, my thanks to the AHA and the Circulation for publishing this paper, we always want to support the AHA, and we're delighted to be here today for these podcasts. The field of omega-3 fatty acids has been a complicated one for a long time. Epidemiology suggested that, fish consumption would lower cardiovascular risk, and there was a number of trials done. And my friend and colleague here at the Brigham, Deepak Bhatt, was the lead of a very big trial, called REDUCE-IT. Some 8,000 plus patients who received EPA alone, and they got a terrific result. A 25% reduction in their primary endpoint. And this was a New England Journal paper, back in 2019 or so. But another friend of mine, Steve Nicholls, ran another large trial of a combination of eicosapentaenoic acid, or EPA, plus docosahexaenoic acid that's DHA called STRENGTH. And that one showed, really, no benefit. And so, there's been some controversy out there. In any event, when Deepak and his colleagues published their original paper, they said it's interesting, because they got this big risk reduction, but it wasn't apparently due to the triglyceride lowering of the drug. And so, my interest, as many people know, has largely been in inflammation biology. And so we said, well maybe we should just do a test. Well, we said, we'll measure a number of biomarkers that we know were associated with atherosclerosis, some inflammatory, some with coagulation. And so, that was the core hypothesis, was simply to look at some other markers, and see what we might learn. And sometimes, you learn things that you didn't expect. And I think, that goes to the heart of what complicated clinical trials are all about. And I'd also say perhaps, what the roles of surrogate endpoints are, as compared to hard clinical endpoints, and things that make this whole field kind of interesting. Dr. Greg Hundley:           Right. Very nice, Paul. So you mentioned REDUCE-IT, so describe a little bit more for your study. What was the study population, and what was your study design? Dr. Paul Ridker: We were fortunate enough to work with REDUCE-IT investigators, to use their biobank. They had put together, again, it's 8,000 plus patients. I think, it was two thirds secondary prevention, one third primary prevention. And when they received the combination of EPA and DHA, as I said earlier, they had about a 25% reduction in the risk of their primary endpoint, which was cardiovascular death, nonfatal AMI, nonfatal stroke, coronary revascularization, and the like. What we did is, we basically said, "Okay, since the mechanism was uncertain, why don't we go ahead and measure a series of biomarkers?" Things that a lot of us are interested in, homocysteine, LPLa, oxidized LDL, my own interest in inflammation. We measured, IL-1β, we measured, IL-6, we measured CRP. We measured another molecule, Lp-PLA2, that people have been interested in. And the hypothesis, of course, was to see what the drug did, as compared to the comparator did. And the findings were interesting to us, in that, to simplify them, the actual icosapent ethyl arm didn't do much to most of those biomarkers, very little change. But the mineral oil comparator arm had some small to modest effects on all those biomarkers, all of which went up again. Now, some of these effects are pretty small, two to 3% for things homocystine, LPLa. Others were moderate, 10 to 20% increases in oxidized LDL, Lp-PLA2. And the inflammatory markers went up about 25%, sometimes, even a little more. So it's complicated. It's important to point out, that these changes on an absolute scale are relatively small. On a percent scale, they're different. The REDUCE-IT investigators themselves, to their credit, had earlier published that, they saw some increase in LDL cholesterol as well, about 10, 11% in those who had received the mineral oil comparator. So it's not exactly what we thought we were going to find, I guess, is the simplest way to express it. Dr. Greg Hundley:           Very nice. And so, describe for us just a little bit more, any differences in men and women, and what about age? Or for example, premenopausal, postmenopausal women. Dr. Paul Ridker: No, the effects were quite consistent across all various subgroups. It's a very large study. There were, again, 8,000 patients, lots of blood samples been drawn. And I should again, commend the REDUCE-IT investigators, for allowing us to do this work with them. And again, as I point out, sometimes you find things out that weren't what you expected. And the hard part, I was glad this got tossed over with Dr. Harrington, is sort to figure out well, what's it really mean? Because again, as a clinical trial list, I will say, my instincts are to trust the primary endpoint of the trial. That's what they did. They're going to go out and lower heart attacks and strokes. And then, here we are a couple years later, trying to figure out what the mechanism might be, and just came across some puzzling results. Dr. Greg Hundley:           Very nice. Well, next listeners, we're going to turn to the editor that actually processed this manuscript, Dr. Allan Jaffe. Allan, what drew you to this particular article? Dr. Allan Jaffe:   Well, I was asked to be a guest editor this week, by the Journal, because of some conflicts that were intrinsic to the editorial board. And since I have an interest in biomarkers, and had for a long time, it made perfect sense for me to become involved. I was particularly interested in this particular area, because I was aware that there were these two trials that had found different endpoints, and that there were some controversy as to what the mechanisms might be by which these effects could occur. And so I was pleased to get involved. And I think it's a compliment to the REDUCE-IT investigators, and to Dr. Ridker, that they were willing to put the data out there so that everybody could see it. And we could then begin to look. So it was of interest to me. I thought it was important to the field, to get really good reviewers who would be, make sure that the data that would eventually be published was clear, so that readers would understand it. And so that, at the end, we'd be able to at least, come to some conclusions that we could end up having an expert in clinical trials. And I thought about Bob Harrington, right from the beginning, might be able to comment on. Dr. Greg Hundley:           Very nice. Well, Bob he's setting you up here nicely, both Paul and Allan, to really help us put these results in perspective with other studies that have been performed in this space. What are your thoughts? Dr. Robert Harrington:   So first off, Greg, thanks for having me. And Allan, thanks for inviting me to review and comment on the paper. As both Allan and Paul have indicated, that I've spent the last 30 plus years doing clinical trials of all sizes. Very small, where we try to understand mechanisms, and very large, where what we're trying to understand is clinical outcomes. And I've been intrigued in this field, because of the inconsistency of the data across the field. Where in some trials, Paul had indicated this STRENGTH, there seemed to be no effect of omega-3 fatty acids, and in REDUCE-IT, there was quite a pronounced effect of the test agent. And so, when one sees discordance in a field, one tries to understand, well, why might that be? And so in the editorial, I took the position that, well, what are we trying to do in clinical trials? And in outcomes trials, we're trying to figure out what matters to patients. Do they live longer? Do they feel better? Do they avoid bad stuff happening to them? Like having to undergo revascularization procedure. So you're trying to do things that are really clinically meaningful, but that doesn't say that you're also not trying to understand mechanism. And as Allan said, there have been some questions raised. And so, trying to understand mechanism in the edit in trials can be quite useful, not just to understand that trial results, but to really form hypothesis for a field going forward. And so, I took the approach of, we learn things from different trials, and sometimes we learn things in the same trial. Meaning that, there's mechanistic work embedded in the large trial. One of the most famous examples of this, in the GUSTO trial 30 years ago, we learned through the mechanistic substudy, that it was rapid reprofusion TIMI-3 establishment of TIMI-3 flow, that really explained the difference between TPA and streptokinase. So I was very intrigued by how we might use these data to explore the results. And I find the findings fascinating, as Paul said. It is complicated, but it raises a really fundamental issue in clinical trials. There's an assumption in a placebo control trial, that because randomization is allowing you to balance everything, except for the randomized treatment groups, and therefore, that comparison has causal information in it. There's an underlying assumption that's really important. And that is, that the placebo is inert. That it has no biological effect of its own. Well, that assumption was violated here. The placebo is not inert in this clinical trial. Now, the investigators, I think to their credit, have said, "Well, this is small, probably doesn't matter." And that might be right, but it also may be wrong. And you can't just say, well, it doesn't matter, these are small effects. As Paul said, some of the effects are small, some are medium, some are large. So what explains it? And I made a point in the editorial, you could model all of this. If you get 5% of this, and 10% of this, and 20% of this, you could make some assumptions and say, well, the magnitude of the benefit was so great that it couldn't have been overcome by this. But that's just modeling, and there's uncertainty. So for me, as a trialist, and somebody who really believes in using evidence to guide practice and to guide public policy, I think there's uncertainty here. It's likely that the treatment effect is not as large as was observed, but how large is it? And how large is important? And how large might we want to consider to put into our practice guidelines? I think all of those open questions, particularly in a field where there is inconsistency across trials, in terms of the observation of the outcome. So my conclusion is, we need more work. We need another trial, if we really want to understand this. And we need to use an inert placebo, to really understand what the contribution was. I'd like nothing better to see that it didn't matter. But I can't say that it doesn't matter because I don't know. Dr. Greg Hundley:           Well, listeners, boy, we've got kind of some interest here in that an unexpected result. So Paul, it's nice doing an interview like this listeners, because each speaker sets up the next one. Paul, Bob is saying, well, what should we do next to clarify the results here? So maybe we'll go through each of you, and start with Paul. Just describe for us, what do you think is the next study that we need to perform? Dr. Paul Ridker: Well, Greg, it's a really interesting issue. We saw it, as authors, to write as neutral a paper as we could possibly write, and sort of do our academic job and say, here are the data. And I think we did it that way because, we don't really know what the interpretation should be. On the one hand, you have a very big beneficial result, which is great for patients. And there's a prior clinical trial called JELIS, which was open label, the same drug, and also got a large benefit. And we were trying to figure out mechanism. That being said, as Bob pointed out, I think what we stumbled into is some level of uncertainty. And the question is, how uncertain would it be, and does it matter in the big picture? Allan was interesting, because the Journal asked us to use the word comparator, rather than placebo. Now this was designed as a placebo controlled trial, but our paper uses the word comparator, because of the possibility, that as Bob Harrington points out, it may not be totally inert. So the writing of this was quite carefully done. I think, at the end of the day, my REDUCE-IT colleagues, who I have great respect for, and really worked terribly hard to do the main trial, understandably feel, that the trial would've showed, and I have a lot of sympathy for that, because it's the hard endpoints we should go with. On the other hand, I have sympathy with the idea that it never hurts to have more data. And if there could be a way to have a second trial, and I might change the population a little bit, maybe I'd do it in true primary prevention. This was one third primary prevention. My colleague, Joanne Manson had done her, she had a trial where they showed some potential benefit in the black populations. Maybe you might over sample some minority groups. But just the pragmatic issues here, make it tough to have a second trial. And so, uncertainty is just part of what we, as physicians, have to learn to live with. Dr. Greg Hundley:           Allan, turning to you. What do you think is a next study to perform in this space? Dr. Allan Jaffe:   Well, I think what Paul has said is correct. That it would be very hard to generate enthusiasm funding for a large trial. But it might not be nearly as difficult to begin to explore the effects of the mineral oil comparator, versus the active agent, versus perhaps, another potential placebo, and see over time what happens in primary prevention patients, as a way of beginning to put some context around what these results might mean. So for example, it could turn out that, the active agent actually kept the values from rising as they normally would've, and mineral oil had no effect at all. Alternatively, mineral oil may well have been a negative. It had a negative effect. And I think, those are the sorts of questions that could be explored reasonably in the short term, without doing another multimillion dollar randomized trial. Dr. Greg Hundley:           And Bob, your thoughts. Dr. Robert Harrington:   Well, and I mentioned this in the editorial, Greg. I didn't make my recommendation lightly. I know that these trials are expensive. I know these trials take a great deal of time, a great deal of energy. And I know that the REDUCE-IT investigators worked enormously hard over the years to get this done. So I don't say tritely, "Oh, just do another trial." But if you think about the magnitude of the public health issue here, there are millions of people to who this kind of therapy might apply globally. And so, shouldn't we be more certain than less certain, if we want to include it, for example, in ACC/AHA guidelines? I would say, the answer to that is yes. And so, I think of it as, okay, let's make some assumptions. Let's assume, that the effect that was observed in JELIS and REDUCE-IT, is the true effect. That's ground truth. Well, there are different study designs one might think about, from an analytic perspective, using Bayesian statistics, as opposed to frequency statistics. One might think about an intense interim analysis plan, to understand where the data are going, and be able to pull in the prior data for evaluation. I would advise getting a smart group of people together, who spend their lives thinking about trials in the atherosclerotic space, and the REDUCE-IT team is pretty darn good, and say, "How could we do this efficiently?" I do think, there's enough uncertainty that it would be ethical, from an equipoise perspective, to include high risk patients in a second evaluation, because we do have uncertainty. And if we really want to nail this down, I think we could look at high risk patients with hypertriglyceridemia, and try to use some interesting design issues, and some interesting analytical issues, to try to reduce the sample size, lot of attention in interim analyses, to try to answer the question. I'd like, as I said, nothing better to say, "Oh look, REDUCE-IT was the truth." This next trial is consistent. That'd be, to me, a terrific outcome of this. On the other hand, if you said to me, "Well, the effect's not 25%, it's more in the 15% range." Well, maybe then we think about how we apply it to our patients a little differently, maybe a little more cautiously. So I don't make the recommendation lightly, as I said, but I do think that there are some conversations that could be had, being respectful of the effort and the expense that goes into these kind of things. To try to answer the question efficiently. Dr. Greg Hundley:           Very nice. Well listeners, we want thank Dr. Paul Ridker, from Brigham and Women's Hospital, Dr. Bob Harrington from Stanford University, Dr. Allan Jaffe, from the Mayo Clinic, for bringing us the results of a substudy of the REDUCE-IT trial, that assessed a variety of serum biomarkers, pertaining to systemic inflammation, and highlighting uncertainty around the mechanism regarding the efficacy of icosapent ethyl, that's been used previously for primary or secondary prevention of cardiovascular events. And next listeners, we are going to move to our second feature discussion and review some data pertaining to microbleeds in the central nervous system, during and after TAVR procedures. Welcome listeners, to our second feature discussion on this August 2nd. And we are going to explore some of the world of TAVR and its potential complications. And we have with us today, Dr. Eric Van Belle, from Lille, France. And also, Dr. Manos Brilakis, from Minneapolis, Minnesota. Welcome gentlemen. And Eric, we'll start with you. Can you describe for us a little, the background information that you use to assemble and construct your study, and describe, or list for us, the hypothesis that you wanted to address? Dr. Eric Van Belle:           Yes. Thanks a lot for the question. So we knew for many years, that some of the complication of the TAVR procedure relate to the brain. And it has been described by many others, that there were some complication in the brain of patient undergoing TAVR. And there was no previous investigation on potential bleeding or microbleeding in this population. And on the other side, there are previous publication on, of course, initially chronic microbleeding, in patient with some of, let's say, disease in the brain, but also, a possibility of acute microbleeding. And especially, in some interesting population relating to the TAVR feed, that is patient with valve disease, patient with endocarditis, or patient with assist device. In this population, microbleedings, acute microbleeding, have been described. And what is interesting, if you look at all these populations, these are population in which the Von Willebrand factor has been impacted and modified, and could be one of the reason of the microbleeding. And one of the similar feature of the patient with aortic stenosis that undergo TAVI, or TAVR, that are patient with indeed also, this kind of Von Willebrand disease. So if we put everything together that is previously, we only looked at antibody complication in those population, and that Von Willebrand disease, which is present in patient with aortic valve stenosis, could promote a bleeding, in particular, bleeding in the brain. We decided to look at the potential appearance of microbleeding, in patient undergoing TAVR procedure. Dr. Greg Hundley:           Very nice. And Eric, can you describe for us, your study design, and who was your study population? Dr. Eric Van Belle:           Yes. So basically, the study population is a basic population of patient undergoing TAVI. Just to make sure that one of the difficulty of this study, was to conduct and perform an MRI, a brain MRI, before the procedure, and as short as possible after the procedure, within three days, which is logistically challenging. And also, to make sure that we keep most of the population to undergo the MRI, we had to exclude patient with a high risk of pacemaker, or patient with pacemaker that could not undergo the MRI. But basically, without this, it's just a regular population. And if we indeed, compare to some of the previous work I was mentioning, about describing the acute MRI, it was important for us to make sure, or to be as sure as we could get, that indeed, this microbleeding, if we observe them, could be related to the procedure. And it means that, the MRI, after the procedure, should be done as short as possible. And also, that an MRI, a baseline MRI, should be performed. Because we know, that in this population, you could have some microbleedings also observed before starting the procedure. Dr. Greg Hundley:           So a cohort study design where MRIs are performed before, and then very soon after, TAVR procedures. So Eric, what did you find? Dr. Eric Van Belle:           So what we observed, the first thing that we confirmed was indeed, that in this population of that age, that is patient around 80 years old, when we do the baseline MRI, you find in about one out of four patients already, some microbleedings. And this was expected, and it is very similar to what is expected in this kind of population. But what was indeed more striking, that when we repeated the MRI after three days, we observed another 23% of patient with a new microbleedings that were observed. This is indeed the most important observation. What was also important that, the patient with microbleedings, and the location of the microbleedings, were not related to the cerebellum brain, because indeed we could observe some cerebellum arise in this population, as it is expected. And there was no relation between the two. So it's also, an important observation, suggesting that this microbleeding are not hemorrhagic transformation of cerebellum brain, for instance. And we also observed that, the risk of microbleeding, or the chance to observe the microbleeding, was increased when the procedure was longer. And also, when the total duration of anticoagulation was longer, we also observed that, when the procedure was, when we used protamine at the end of the procedure, the risk of microbleeding was less. And also, importantly, the status of the Von Willebrand factor, and indeed, an alteration of the multimer of Von Willebrand factor, was also associated with the risk of microbleeding in this population. Dr. Greg Hundley:           Very nice. So in this cohort of 84 individuals, average age around 80, undergoing TAVR procedure, and about 50/50 men and women, you had several factors. Prior history of bleeding, amount of heparin, absence of protamine, all indicating a higher risk of these microbleeds. So very practical information. Well, Manos, you have many papers come across your desk. What attracted you to this particular paper? And then secondly, how do we put these results really, in the context of maybe other complications that can occur during or after TAVR procedures? Dr. Emmanouil Brilakis: Yes, thanks so much, Greg. And also, congratulations Eric, for a wonderful paper, and thanks for sending it to circulation. I think, with increasing the number of targets, as you know, TAVR now is becoming the dominant mode for treating severe aortic stenosis. Safety is of paramount importance. And even though there's been a lot of progress, we still have issues with the safety of the procedure. So understanding how can make it safer is very important. And I think, what was unique in this paper, again, congratulations for creating this study, is that it opens a new frontier. We worry about stroke. We're all very worried about the stroke, and having the patient have a permanent neurologic damage during the procedure. But there may be more to it than the classic embolic stroke. And I think, this study opens actually, a new frontier with the micro cerebral bleeds. Now we don't completely understand, despite the study, we don't understand the functional significance from this. And I think, that's one of the areas that will need further research. But I think, trying to understand what causes them, and preventing those microbleeds, would have a very important role in the future, for making TAVR even safer than it is. Dr. Greg Hundley:           Very nice. Well, Manos, you really lead us into the kind of the next question. So Eric, what do you see as the next study to be performed in this sphere of research? Dr. Eric Van Belle:           Again, to me, and to follow with the comment of Manos, we need to include, I would say, to solve two questions. We have to solve the question of, what could really impact these microbleedings. And what would be the impact of this microbleeding on the long term outcome of this patient? So it's means that we have to set, as part of the studies that we will design, potentially studies on aortic immolation. Or let's say for instance, we could investigate the role of protamine. It has been suggested that protamine could be something interesting, so it could be tested as part of a randomized study. But this means that, as part of such randomized study on the use of protamine, for instance, you would include a last cohort of patients with MRI after the procedure. And also, a long term follow of the neurological complication, which indeed, is the missing part of our current study. We would need to have a much larger cohort of patients, to be able to reconnect the neurological outcome to the MRI outcome, and also to include this. So let's say, for me, one of the studies we would be interested to perform, is to conduct a study on the use of protamine, which is very simple, randomized, yes or no, and includes brain MRI in this population, as a systematic investigation, which is difficult to conduct. You have to know that it's difficult to do, but it will be very important. And then, to look at the long term neurological outcome. Dr. Greg Hundley:           And I see, Eric, you mentioned the long term, because really in the short term, so within six months, you really didn't see any changes in neurological functional outcome or quality of life. So Manos, just coming back to you. What do you see is the next study that should be performed in this space? Dr. Emmanouil Brilakis: Yeah, I agree actually, with Eric. The next step is, this was an 80 patient study. Right? It's a very small preliminary data, all that opens a new system for evaluation, we're still a very small number of patients. So having a larger number of patients, I think for me, the key thing is to understand the connection. Does this actually cause neurologic symptoms? What does it mean having a microbleed? I think right now, we're still confused on the study. There was not really much impact on the neurologic status of the patient. So for me, the number one thing is, to understand how it impacts the patient's quality of life, the neurologic status. Perhaps more sensitive studies, neurocognitive studies, to understand exactly how it impacts. And then after doing that, I agree with Eric, if this is a bad, something really bad, then we can find different ways to prevent them from happening. Protamine is one of them during the procedure time, and not be a very feasible one. Or it could be interesting to see if different valves, for example, have different propensity for causing those microbleeds. Dr. Greg Hundley: Very nice. Well listeners, we want to thank Dr. Eric Van Belle, from Lille, France, and also, our own associate editor, Dr. Manos Brilakis, from Minneapolis, Minnesota for bringing this very important study, highlighting that one out of four patients undergoing TAVR has cerebral microbleeds before the procedure. And then, after the procedure, one in four patients develop new cerebral microbleeds. And then, procedural and antithrombotic management, and persistence of acquired Von Willebrand factor defects, were associated with the occurrence of these new cerebral microbleeds. Well, on behalf of Carolyn and myself, we want to wish you a great week, and we will catch you next week On the Run. Dr. Greg Hundley:           This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors, or of the American Heart Association. For more, please visit ahajournals.org.

Nous voilà dans le XXe arrondissement de Paris. La rue du Télégraphe doit son nom à son invention créé par Claude Chappe. La première ligne de télégraphe entre Paris et Lille a été inaugurée ici avec un premier qui a mis 9 minutes à parcourir 225 kilomètres. Tout l'été, Entrez dans Paris avec Lorànt Deutsch. Chaque jour dans ce podcast, découvrez en moins de 2 minutes l'histoire d'une rue de la capitale.

durée : 01:57:00 - Les Matins - par : Nicolas Herbeaux, Guillaume Erner, Baptiste Muckensturm, Jean Leymarie - Ce jeudi 28 juillet marque la fin de la tournée africaine d'Emmanuel Macron, quel bilan ? quelles perspectives ? / A l'occasion du Banquet du livre d'été de Lagrasse, nous recevons l'écrivain Yannick Haenel et la poétesse Laura Vasquez. - invités : Yannick Haenel Ecrivain; Seidik Abba journaliste-écrivain, chroniqueur au Monde Afrique.; Alain Antil Directeur du centre Afrique subsaharienne à l'IFRI, enseignant à l'Institut d'Etudes Politiques de Lille et à Paris I Sorbonne

Mauro Bonazzi insegna Storia della Filosofia Antica all'Università di Utrecht e all'Università Statale di Milano. Ha insegnato anche a Clermont-Ferrand, Bordeaux, Lille e all'École Pratique des Hautes Études di Parigi. È un esperto del pensiero politico antico, di Platone e del platonismo. Tra le sue pubblicazioni ricordiamo: Atene, la città inquieta, Piccola filosofia per tempi agitati, I sofisti e Creature di un sol giorno. Collabora con il “Corriere della Sera”.

Le département c'est le Nord. Et nous allons nous balader dans la partie française des Flandres. Lille Flandres c'est le nom de la gare historique de Lille. Et en découvrant la façade, on se dit qu'elle a pris des airs de gare du Nord. Et c'est loin d'être un hasard ! Toutes les explications dans cette émission. Vous aimez les moules ? Vous aimez les frites ? Vous allez forcément adorez les moules-frites du Nord présentés, par Louise Petitrenaud. Ecoutez RTL vous régale avec Jean-Michel Zecca, Jean-Sébastien Petitdemange et Louise Petitrenaud du 14 juillet 2022

Le 3 juillet, après des rumeurs laissant entendre que Zinedine Zidane pourrait devenir le nouvel entraîneur du PSG, c'est finalement Christophe Galtier qui succède officiellement à l'Argentin Mauricio Pochettino.Au fil des années et des clubs, Christophe Galtier est devenu un entraîneur respecté. D'abord à l'AS Saint-Etienne, où il reste pendant 9 ans et qui décroche avec lui la coupe de la Ligue en 2013. Puis à Lille, un club en mauvaise posture qu'il requinque dès 2017 jusqu'au titre de champion de France.L'enjeu est de taille pour l'entraîneur de 55 ans, sacré à trois reprises meilleur coach du championnat de France, qui a la lourde tâche de mettre les rangs parisiens en ordre de bataille pour décrocher la victoire tant attendue en Ligue des Champions.Pour Code source, Dominique Sévérac et Stéphane Bianchi, journalistes au service des sports du Parisien, retracent le parcours de ce meneur d'hommes. Crédits. Direction de la rédaction : Pierre Chausse - Rédacteur en chef : Jules Lavie - Production : Raphaël Pueyo, Lolla Sauty et Thibault Lambert - Réalisation et mixage : Julien Montcouquiol - Musiques : François Clos, Audio Network, Epidemic Sound - Identité graphique : Upian - Archives : BeIn Sport Europe 1, Canal +. Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

Baptiste from @leclassiquepod and our host, Jeremy Magan, discuss the 5 "new" coaches in Ligue 1 - Galtier at PSG, Favre at Nice, Le Bris at Lorient, Fonseca at Lille and Tudor at Marseille --- Send in a voice message: https://anchor.fm/breaking-the-lines/message

Après une journée de repos, le Tour de France repart ce mardi dans les Alpes; Romain Bardet, ambitieux, se livre dans L'Équipe et promet deux dernières semaines de course animées; Pogba officialisé, Bayo arrive à Lille, le mercato se poursuit partout en Europe; Moussa Sissoko se confie dans votre journal au sujet de son transfert au FC Nantes. Retrouvez toute l'actualité sportive dans votre Flash L'Équipe. 

Dette års regionalstævne har temaet "Søg fred". Men som sædvanligt gemmer der sig noget dystert bag de umiddelbart fredelige ord. Stephen Lett, medlem af Det Styrende Råd, melder ud i sin indledning, hvordan vi skal betragte andre mennesker - selv babyer.

La mobilité constitue un enjeu majeur pour le climat. C'est, par exemple, la première source d'émission de gaz à effet de serre, en France, soit 135 millions de tonnes. Et 70% de ces émissions proviennent des voitures et des camionnettes. Les transports sont aussi le seul secteur à avoir augmenté ses émissions de CO2 depuis 30 ans. Alors que l'urbanisation continue de croître, la nécessité de développer d'autres modes de mobilité plus durable et de réduire la dépendance à la voiture est de plus en plus forte. Des pays comme les Pays-Bas ou les pays scandinaves ont très tôt développé la pratique du vélo. Alors que les prix des carburants augmentent, en lien avec la guerre en Ukraine, quelles solutions s'offrent à nous pour nous déplacer sans polluer et à moindre coût ? Comment réaménager des villes jusque-là construites pour la voiture ? Avec - Frédéric Héran, économiste des Transports à l'Université de Lille 1, chercheur au Centre lillois d'études et de recherches sociologiques et économiques - Julien De Labaca, consultant en mobilité, fondateur du Cabinet de conseil Le facilitateur de mobilité. ► Un entretien avec Laure Broulard, correspondante de RFI à Kigali pour parler du système de vélos en libre-service de la ville. Programmation musicale : ► Diom Gnakou Fi - Cheikh Ibra Fam, Mo'Kalamity ► Watina - Calypso Rose.

REDIFFUSION :In French in this CDA S2#1 : Portrait of the Coldefy agencyIn English in CDA S2#2 : The Pulse National Memorial & Museum, Orlando USA project by ColdefyEn français dans ce CDA S2#1 : Portrait de l'agence ColdefyEn anglais dans le CDA S2#2 : Le projet du Pulse National Memorial & Museum, Orlando USA par Coldefy___Comme Obélix, ils sont tombés dans la potion magique étant enfant!C'est sans doute pour cela qu'Isabel Van Haute et Thomas Coldefy se sont trouvés tant dans la vie professionnelle que dans la vie personnelle. De cette complicité hors norme, l'une des agences d'architecture françaises comptant parmi les plus dynamiques aujourd'hui a pu éclore. L'agence aux origines était lilloise. Elle l'est toujours mais a monté une antenne à Paris, puis à Hong Kong et enfin à Shanghai! Ancrée à Lille, elle signe des bâtiments aux quatre coins de la planète.Parmi les projets de l'agence :. 169 logements, Montalembert, Villeneuve d'Ascq, France. Fondation de Chine, Cité internationale universitaire de Paris, France. Wonder Building à Bagnolet, France. Space XL, Villeneuve d'Ascq, France. Natural History Museum, Shenzhen, Chine. The Pulse National Memorial & Museum, Orlando, USA (...)Au micro de Com d'Archi, Isabel et Thomas racontent leur parcours, le travail de toute l'équipe, avec générosité et passion.Portrait DR © Com d'Archi PodcastIngénierie son : Julien Rebours____ Si le podcast COM D'ARCHI vous plaît n'hésitez pas :. à vous abonner pour ne pas rater les prochains épisodes,. à nous laisser des étoiles et un commentaire, :-),. à nous suivre sur Instagram @comdarchipodcast pour retrouver de belles images, toujours choisies avec soin, de manière à enrichir votre regard sur le sujet.Bonne semaine à tous ! Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

Tom Canton is joined by Bailey Keogh to dissect the latest Arsenal news, including last night's reported offer for Lille winger Edon Zhegrova and whether Arsenal are looking for a budget decision after making a Youri Tielemans decision.Plus, they discuss Hector Bellerin's future at the club and whether he will run his contract down to move to Real Betis on a free, as well as looking at the Lisandro Martinez deal and asking should the Gunners put a deadline on the deal? Enjoy!

L'étape d'aujourd'hui s'élance donc de Lille Métropole. Qu'il est pale ce mot Métropole, et Lille a tant de couleurs. Nous dirons donc Lille. Et l'arrivée se juge 155 bornes plus loin à Wallers-Arenberg. Tel est le nom de la commune. Nous tenons ici aux noms des communes, des villages, des lieux-dits. Le reste, on s'en fout. Arenberg est la commune des gueules noires, des mineurs, et comment ne pas se souvenir de Jean Stablinski (...) Avant d'être un forçat de la route, il a été une gueule noire. La trouée d'Arenberg, il est le seul coureur à être passé dessus et dessous, disait-il. Durant toute la durée du Tour de France (1er-24 juillet), retrouvez chaque matin à 7h30 sur RTL l'échappée belle de Christian Laborde, écrivain passionné de cyclisme, amoureux de la Grande Boucle et de ses innombrables anecdotes.

Tour de France 2022.  Stage 5 Lille to Waller-Arenberg (157km).  Cobbles and carnage.  Who wins, who lost their shot at yellow and who is still in the game.  #TDF22   #stage5 Episode 251 Subscribe to our Podcast YouTube Channel. Find our audio links here: http://podcast.between2wheels.com/p/podcasts-1512193552/ Follow and share us on Facebook at: https://www.facebook.com/between2wheels/ Find us on twitter @b2w_podcast or Email: admin@between2wheels.com Website: www.between2wheels.com It is our desire to bring you funny and insightful commentary and interviews of cycling from around the world but with a focus on Northern California. Please like, subscribe and share the podcast.  We will only get better with time and some input from those listening

In a bumper episode of The Cycling Podcast from the Tour de France, Lionel Birnie and Mitch Docker hit the pavé to capture the atmosphere and convey the chaos of the race as the riders hit the cobblestones. Mitch's final race as a professional was Paris-Roubaix back in October but this is his first time watching a race on the cobblestones of the Hell of the North from the roadside. They are then reunited with François Thomazeau to unravel a dramatic day on the cobbles. Who were the winners, who were the losers and where does the Tour go from here? The Cycling Podcast is supported by Supersapiens and Science in Sport. Supersapiens Supersapiens is a continuous glucose monitoring system that helps you make the right fuelling choices. See supersapiens.com Science in Sport For 25% off all your SiS products, go to scienceinsport.com and enter the code SISCP25 at the checkout. Noom If you want to transform your diet, undo some bad eating habits or just get a better handle on the amount and types of food you are eating, like Lionel, you might want to try Noom. It's the psychological approach to losing weight in a healthy, sustained way. Go to noom.com/cycle to get started today. MAAP The Cycling Podcast has a new collaboration with MAAP. We have launched the first of the three MAAP + The Cycling Podcast jerseys. Go to maap.cc for more details and to vote for your favourite. Friends of the Podcast Sign up as a Friend of the Podcast at thecyclingpodcast.com to listen to more than 60 exclusive episodes. The Cycling Podcast is on Strava The Cycling Podcast was founded in 2013 by Richard Moore, Daniel Friebe and Lionel Birnie.

Le pouvoir d'achat des Français est mis à mal par une inflation qui ne cesse d'augmenter. C'est dans ce contexte que le ministre des Finances propose un plafonnement des loyers. Comme l'encadrement des loyers, dans certaines villes, cette nouvelle mesure les empêche d'augmenter librement. Limiter l'envol des loyers Liée notamment aux conséquences de la guerre en Ukraine, l'inflation ne cesse de progresser, en France comme ailleurs. Elle ne provoque pas seulement l'augmentation du prix des carburants ou des denrées alimentaires. Elle entraîne aussi une hausse notable des loyers. Or le loyer représente, en moyenne, plus du tiers du budget mensuel des Français. Aussi le gouvernement se devait-il de prendre des mesures pour limiter, dans ce domaine sensible, l'impact de l'inflation. C'est ce que vient de faire le ministre des Finances. Bruno Le Maire vient en effet de proposer un plafonnement des loyers. Ils ne devraient pas augmenter de plus de 3,5 % sur un an. Ce" "bouclier loyers" sera intégré à la loi sur le pouvoir d'achat que le gouvernement devrait présenter cet été au Parlement. Sans ce plafonnement, les loyers auraient pu augmenter, d'après le ministre, de 4 à 6 %. Une mesure qui s'ajoute à l'encadrement des loyers Cette mesure empêche les loyers de suivre l'indice du coût de la construction, qui, en règle générale, sert de référence pour fixer leur progression. Comme cet indice suit l'inflation, il aurait dû en effet, sans ce plafonnement, augmenter davantage. Mais il est d'autres dispositions qui empêchent les loyers d'augmenter librement, c'est-à-dire en se référant à l'indice de la construction. En effet, dans certaines villes, comme Paris, Lille ou Lyon, les loyers sont encadrés. Il s'agit d'agglomérations où, du fait d'une demande supérieure à l'offre, ces loyers sont plus élevés que la moyenne. Parallèlement au plafonnement des loyers, le gouvernement se propose d'augmenter de 3,5 % l'Aide personnalisée au logement (APL). Ces mesures ne sont pas jugées suffisantes par les associations de locataires, qui auraient préféré un gel des loyers. Elles déplorent que les pouvoirs publics aient choisi d'augmenter les revenus des propriétaires, au détriment de ceux des locataires. Learn more about your ad choices. Visit megaphone.fm/adchoices

In deze Zomerse versie van de FC Afkicken Podcast is Yordi Yamali te gast bij Bruce Tol! De stem van voetbalpodcasts Hekkensluiters en Tekengeld komt langs voor een bomvolle aflevering. Zo gaat het onder meer over het vertrek van Sinisterra naar Leeds, Ten Hag die een "Van Gaal-tje" aan het pullen is, het hoofdpijndossier Cristiano Ronaldo, de transfer van Wout Weghorst naar Turkije en het vertrek van Pochettino bij PSG!(00:00) Intro en Football Manager avonturen(02:21) Tekengeld(03:47) Sinisterra vertrekt naar Leeds(09:26) Wat doet Feyenoord met het geld voor Malacia en Sinisterra?(14:32) Erik ten Hag blijft het bij bekende namen zoeken(21:39) Hoofdpijndossier Cristiano Ronaldo(23:28) Weinig aandacht voor Weghorst(27:47) Zeki Çelik van Lille naar Roma(29:28) WK-selectie Hakim Ziyech en welke transfer moet hij maken?(32:38) Waarom willen spelers geen grote ster in de subtop meer zijn?(37:55) Pochettino en PSG nu toch echt uit elkaar(42:56) AfsluitingZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

The Cycling Podcast's weekend break in Denmark comes to a close in Sønderborg where the locals have almost drunk the bars dry after a day celebrating the Tour de France. Join Lionel Birnie, François Thomazeau and Mitch Docker as they recap a sprint stage with a twist. We also catch up with Kate Wagner, who spent the day chasing the peloton on a motorbike, and we look at the logistics as the race transfers back to Lille. The Cycling Podcast is supported by Supersapiens and Science in Sport. Supersapiens Supersapiens is a continuous glucose monitoring system that helps you make the right fuelling choices. See supersapiens.com Science in Sport For 25% off all your SiS products, go to scienceinsport.com and enter the code SISCP25 at the checkout. Babbel If you would like to learn a foreign language, you might like Babbel for its bite-sized lessons. Get six months free with the purchase of a six-month subscription at babbel.com/play with the promo code CYCLE MAAP The Cycling Podcast has a new collaboration with MAAP. We have launched the first of the three MAAP + The Cycling Podcast jerseys. Go to maap.cc for more details and to vote for your favourite. Friends of the Podcast Sign up as a Friend of the Podcast at thecyclingpodcast.com to listen to more than 60 exclusive episodes. The Cycling Podcast is on Strava The Cycling Podcast was founded in 2013 by Richard Moore, Daniel Friebe and Lionel Birnie.

Les notes du podcast: https://sesentirbien.coach/podcast/213/ Debora: https://www.instagram.com/simplement.debora/ Isa: https://www.instagram.com/aventures__en__conscience/ Lille: https://www.instagram.com/apprendreamourir/ Rejoindre la communauté (35 euros/mois): https://sesentirbien.coach/coaching/la-communaute-standard/ Rejoindre la communauté Premium (coaching individuel 200 euros/mois pour 2 séances de 45min): http://sesentirbien.coach/coaching/la-communaute-premium/ Prendre une séance avec moi: https://sesentirbien.coach/coacher-avec-esther-taillifet/ Les ateliers et autres évènements: https://sesentirbien.coach/evenements Me suivre sur Instagram: https://www.instagram.com/esthertaillifet/